source: internationalization/trunk/TranslationSpreadsheets/WV-DIALOG-0231.txt@ 604

Last change on this file since 604 was 604, checked in by George Lilly, 15 years ago

Internationalization

File size: 12.8 KB
Line 
1English French Notes Complete/Exclude
2 TYPE OF IMMUNOTHERAPY (BRM):
3TYPE OF FIRST RECURRENCE
4DATE OF FIRST RECURRENCE
5DISTANT SITE(S) OF FIRST RECURRENCE
6TABLE V - FIRST RECURRENCE
7387TYPE OF FIRST RECURRENCE/BLADDER..
8DATE OF FIRST RECURRENCE..........:
970DATE OF FIRST RECURRENCE.........
10DISTANT SITE(S) OF RECURRENCE:
1171.1 RECURRENCE SITE 1...........
12 RECURRENCE SITE 2...........: None
13 RECURRENCE SITE 3...........: None
1471.2 RECURRENCE SITE 2...........
1571.3 RECURRENCE SITE 3...........
16DATE OF LAST CONTACT OR DEATH
17VITAL STATUS
18CANCER STATUS
19REVIEWED BY CANCER COMMITTEE
20TABLE VI - STATUS AT LAST CONTACT
21DATE OF LAST CONTACT OR DEATH.......:
2215VITAL STATUS........................
23CANCER STATUS.......................:
2481COMPLETED BY........................
2582REVIEWED BY CANCER COMMITTEE........
26ACCESSION/SEQUENCE NUMBER...........:
27CLASS OF CASE.......................:
28PATIENT REFERRED FOR TREATMENT......:
29ZIP CODE AT DIAGNOSIS...............:
30BIRTHDATE...........................:
31RACE................................:
32SPANISH ORIGIN......................:
33SEX.................................:
34PRIMARY PAYER AT DIAGNOSIS..........:
35LENGTH OF STAY......................:
36 HEAD AND NECK:
37SMOKING HISTORY.....................:
38DURATION OF SMOKING HISTORY.........:
39DURATION OF SMOKE FREE HISTORY......:
40TABLE II - DIAGNOSTIC INFORMATION
41 GROSS HEMATURIA...................:
42 MICROSCOPIC HEMATURIA.............:
43 URINARY FREQUENCY.................:
44 BLADDER IRRITIBILITY..............:
45ONSET OF SYMPTOMS...................:
46DURATION OF SYMPTOMS:
47 GROSS HEMTURIA....................:
48 BIMANUAL EXAMINATION OF BLADDER...:
49 CYSTOSCOPY WITH BIOPSY............:
50 CYSTOSCOPY WITHOUT BIOPSY.........:
51 FLOW CYTOMETRY....................:
52 INTRAVENOUS PYELOGRAM.............:
53 URINE CYTOLOGY....................:
54DATE OF INITIAL DIAGNOSIS...........:
55SPECIALTY MAKING DIAGNOSIS..........:
56PRIMARY SITE (ICD-O-2)..............:
57HISTOLOGY (ICD-O-2).................:
58GRADE...............................:
59TABLE III - EXTENT OF DISEASE AND AJCC STAGE
60 ABDOMINAL ULTRASOUND:
61CT OTHER............:
62 BONE IMAGING........:
63MRI PELVIS/ABDOMEN..:
64MRI OTHER...........:
65 CT CHEST/LUNG.......:
66OTHER...............:
67 CT ABDOMEN/PELVIS...:
68PRESENCE OF HYDRONEPHROSIS..........:
69TUMOR SIZE (mm).....................:
70PRESENCE OF MULTIPLE TUMORS.........:
71REGIONAL NODES EXAMINED.............:
72REGIONAL NODES POSITIVE.............:
73SITE(S) OF DISTANT METASTASIS:
74 SITE OF DISTANT METASTASIS #1.....:
75 SITE OF DISTANT METASTASIS #2.....:
76 SITE OF DISTANT METASTASIS #3.....:
77 AJCC STAGE........................:
78 CLINICAL STAGE....................:
79 PATHOLOGIC STAGE..................:
80Print Bladder PCE
81 PCE Study of Cancers of the Urinary Bladder
82PROTOCOL ELIGIBILITY STATUS.........:
83 PRIMARY PHYSICIAN.................:
84 SECONDARY PHYSICIAN...............:
85 TUMOR RESECTION DURING TURB.......:
86 TYPE OF URINARY DIVERSION.........:
87 PELVIC LYMPH NODE DISSECTION......:
88 BLEEDING REQUIRING TRANSFUSION..:
89 DEEP VENOUS THROMBOSIS..........:
90 MYOCARDIAL INFARCTION/ARRHYTHMIA:
91 PELVIC ABSCESS..................:
92 PNEUMONIA REQUIRING ANTIBIOTICS.:
93 POST-OPERATIVE DEATH (30 DAYS)..:
94 PULMONARY EMBOLISM/THROMBOSIS...:
95 DATE RADIATION THERAPY ENDED......:
96 TOTAL RAD (cGy/rad) DOSE..........:
97 REGIONAL TREATMENT MODALITY.......:
98 URINARY INCONTINENCE............:
99 RADIATION BOWEL INJURY..........:
100 DATE CHEMOTHERAPY ENDED...........:
101 ROUTE CHEMOTHERAPY ADMINISTERED...:
102IFOSFAMIDE......:
103METHOTREXATE....:
104TAXOL...........:
105THIOTEPA........:
106VINBLASTINE.....:
107 GALLIUM NITRATE.:
108OTHER...........:
109 INDICATION FOR ADMIN OF AGENTS...:
110 REASON CHEMOTHERAPY STOPPED......:
111TYPE OF FIRST RECURRENCE............:
112DATE OF FIRST RECURRENCE............:
113DISTANT SITE OF FIRST RECURRENCE 1..:
114DISTANT SITE OF FIRST RECURRENCE 2..:
115DISTANT SITE OF FIRST RECURRENCE 3..:
116DATE OF LAST CONTACT OR DEATH......:
117VITAL STATUS.......................:
118CANCER STATUS......................:
119COMPLETED BY.......................:
120REVIEWED BY CANCER COMMITTEE.......:
121The Accession Year is not 1998.
122The Diagnostic Confirmation code is not 1 (Positive histology).
123The Class of Case code is not 1, 2 or 6.
124The Behavior Code is not 2 (In situ) or 3 (Malignant).
125Sex is neither 1 (Male) nor 2 (Female).
126Female patient has neither DCIS nor AJCC tumor size of T1mic or T1a.
127Select Table
128 1998 Patient Care Evaluation Study of Breast Cancer
1291998 Patient Care Evaluation Study of Breast Cancer
1301. INSTITUTION ID NUMBER
1312. ACCESSION NUMBER
1323. SEQUENCE NUMBER
1334. POSTAL CODE AT DIAGNOSIS
1345. DATE OF BIRTH
1357. SPANISH ORIGIN
1369. PRIMARY PAYER AT DIAGNOSIS
13710. FAMILY HISTORY OF BREAST CANCER
13811. (F) PERSONAL HISTORY OF BREAST CANCER
13912. SYNCHRONOUS BREAST CANCER
14013. PERSONAL HISTORY OF OTHER CANCER
14114. (F) HORMONE REPLACEMENT THERAPY
14215. (F) HOW MANY YEARS OF HORMONE REPLACEMENT THERAPY
143 1. INSTITUTION ID NUMBER
144 2. ACCESSION NUMBER
145 3. SEQUENCE NUMBER
146 4. POSTAL CODE AT DIAGNOSIS
147 5. DATE OF BIRTH
148 7. SPANISH ORIGIN
149 9. PRIMARY PAYER AT DIAGNOSIS
150 1. INSTITUTION ID NUMBER..........: H6
151 TABLE I - GENERAL INFORMATION
152 2. ACCESSION NUMBER...............:
153 3. SEQUENCE NUMBER................:
1549 4. POSTAL CODE AT DIAGNOSIS.......
155 5. DATE OF BIRTH..................:
1569 7. SPANISH ORIGIN.................
15718 9. PRIMARY PAYER AT DIAGNOSIS.....
158 10. FAMILY HISTORY OF BREAST CANCER:
159901 MATERNAL AUNT..................
160902 MATERNAL GRANDMOTHER...........
161904 ONE SISTER ONLY................
162905 MORE THAN ONE SISTER...........
163908 POSITIVE FAMILY HISTORY, NOS...
164 11. (F) PERSONAL HISTORY OF BREAST
165 CANCER.........................: (Data Item for Females Only)
166909 11. (F) PERSONAL HISTORY OF BREAST CANCER.........................
167910 12. SYNCHRONOUS BREAST CANCER......
168 13. PERSONAL HISTORY OF OTHER CANCER:
169 OVARY (F)......................: (Data Item for Females Only)
170 UTERUS (F).....................: (Data Item for Females Only)
171 PROSTATE (M)...................: (Data Item for Males Only)
172 14. (F) HORMONE REPLACEMENT THERAPY: (Data Item for Females Only)
173916 14. (F) HORMONE REPLACEMENT THERAPY
174 15. (F) HOW MANY YEARS OF HORMONE
175 REPLACEMENT THERAPY............: NA
176 REPLACEMENT THERAPY............: Unknown
177 REPLACEMENT THERAPY............: (Data Item for Females Only)
178917 15. (F) HOW MANY YEARS OF HORMONE REPLACEMENT THERAPY............
179 GO TO ITEM NUMBER:
180 CHOOSE FROM:
18116. CLASS OF CASE
18217. DIAGNOSTIC EVALUATION
18318. (F) TYPE OF MAMMOGRAM
18419. (F) PRESENTATION OF MOST DEFINITIVE MAMMOGRAM
18520. DATE OF INITIAL DIAGNOSIS
18621. DATE OF PATHOLOGIC DIAGNOSIS
18722. PRIMARY SITE (ICD-O-2)
18824. BEHAVIOR CODE(ICD-O-2)
18925. IF INVASIVE DUCTAL CARCINOMA REPORTED, IS DCIS ALSO PRESENT
19027. ARCHITECTURE PATTERN IF DCIS IS PRESENT
19128. NUCLEAR GRADE IF DCIS IS PRESENT
19229. DIAGNOSTIC CONFIRMATION
19330. (M) LEVEL OF INVOLVEMENT
19431. BIOPSY PROCEDURE
19533. PALPABILITY OF PRIMARY
19634. FIRST DETECTED BY
19724. BEHAVIOR CODE (ICD-O-2)
198 TABLE II - INITIAL DIAGNOSIS
199 16. CLASS OF CASE.................:
200 17. DIAGNOSTIC EVALUATION:
201 MAMMOGRAM (M).................: (Data Item for Males Only)
202 18. (F) TYPE OF MAMMOGRAM:
203 A. MAMMOGRAM GIVEN, TYPE UNKNOWN.: (Data Item for Females Only)
204 B. SCREENING MAMMOGRAM...........: (Data Item for Females Only)
205 C. DIAGNOSTIC MAMMOGRAM..........: (Data Item for Females Only)
206 D. MAGNIFICATION MAMMOGRAM.......: (Data Item for Females Only)
207918 A. MAMMOGRAM GIVEN, TYPE UNKNOWN.
208920 B. SCREENING MAMMOGRAM...........
209922 C. DIAGNOSTIC MAMMOGRAM..........
210924 D. MAGNIFICATION MAMMOGRAM.......
211 19. (F) PRESENTATION OF MOST
212 DEFINITIVE MAMMOGRAM..........: (Data Item for Females Only)
213928 19. (F) PRESENTATION OF MOST DEFINITIVE MAMMOGRAM..........
214 20. DATE OF INITIAL DIAGNOSIS.....:
215929 21. DATE OF PATHOLOGIC DIAGNOSIS..
216 22. PRIMARY SITE (ICD-O-2)........:
217 24. BEHAVIOR CODE (ICD-O-2).......:
218 25. IF INVASIVE DUCTAL CARCINOMA
219 REPORTED, IS DCIS ALSO PRESENT: NA, reported tumor not invasive DC
220930 25. IF INVASIVE DUCTAL CARCINOMA REPORTED, IS DCIS ALSO PRESENT
221931 27. ARCHITECTURE PATTERN IF DCIS IS PRESENT....................
222932 28. NUCLEAR GRADE IF DCIS IS PRESENT.......................
223 26. DIAGNOSTIC CONFIRMATION.......:
224 30. (M) LEVEL OF INVOLVEMENT:
225 SKIN..........................: (Data Item for Males Only)
226 CHEST WALL....................: (Data Item for Males Only)
227 PECTORAL MUSCLES..............: (Data Item for Males Only)
228 DERMAL/LYMPHATIC..............: (Data Item for Males Only)
229934 CHEST WALL....................
230935 PECTORAL MUSCLES..............
231 DIAGNOSTIC AND STAGING PROCEDURES
232141 31. BIOSPY PROCEDURE..............
233 32. GUIDANCE......................: Not guided, no biopsy
234 32. GUIDANCE......................: Unknown/death cert only
235143 33. PALPABILITY OF PRIMARY........
236144 34. FIRST DETECTED BY.............
23735. (M) DNA INDEX/PLOIDY
23836. ESTROGEN RECEPTOR PROTEIN
23937. PROGESTERONE RECEPTOR PROTEIN
24038. (M) ANDROGEN RECEPTOR PROTEIN
24139. TYPE OF TEST
242 TABLE III - TUMOR MARKERS AND PROGNOSTIC TESTS
243 35. (M) DNA INDEX/PLOIDY.........: (Data Item for Males Only)
244937 35. (M) DNA INDEX PLOIDY.........
245 36. ESTROGEN RECEPTOR PROTEIN....:
246 37. PROGESTERONE RECEPTOR PROTEIN:
247 38. (M) ANDROGEN RECEPTOR PROTEIN: (Data Item for Males Only)
248940 38. (M) ANDROGEN RECEPTOR PROTEIN
249 39. TYPE OF TEST.................: Neither ERA nor PRA was done
250 39. TYPE OF TEST.................: Unknown if ERA/PRA was done
251941 39. TYPE OF TEST.................
25240. SIZE OF TUMOR (mm)
25341. SIZE OF DCIS TUMOR (mm)
25442. REGIONAL NODES EXAMINED
25543. REGIONAL NODES POSITIVE
25644. SENTINEL NODE BIOSPY
25745. NUMBER OF SENTINEL NODES EXAMINED
25846. NUMBER OF SENTINEL NODES POSITIVE
25947. SENTINEL NODE DETECTED BY
26048. AJCC CLINICAL STAGE (cTNM)
26149. AJCC PATHOLOGIC STAGE (pTNM)
26250. STAGED BY
263 TABLE IV - EXTENT OF DISEASE AND AJCC STAGE
26429 40. SIZE OF TUMOR (mm).......
265 41. SIZE OF DCIS TUMOR (mm)..: NA, reported tumor not invasive DC
266942 41. SIZE OF DCIS TUMOR (mm)..
26733 42. REGIONAL NODES EXAMINED..
26832 43. REGIONAL NODES POSITIVE..
269 SENTINEL NODES
270943 44. SENTINEL NODE BIOPSY.....
271 45. NUMBER OF SENTINEL NODES
272 46. NUMBER OF SENTINEL NODES
273 POSITIVE.................: None examined
274 47. SENTINEL NODE DETECTED BY: NA, not done
275 EXAMINED.................: Unknown if examined
276 POSITIVE.................: Unknown if positive
277 47. SENTINEL NODE DETECTED BY: Method unknown
278944 45. NUMBER OF SENTINEL NODES EXAMINED.................
279945 46. NUMBER OF SENTINEL NODES POSITIVE.................
280946 47. SENTINEL NODE DETECTED BY
281 48. AJCC CLINICAL STAGE (cTNM):
282 49. AJCC PATHOLOGIC STAGE (pTNM):
283 50. STAGED BY:
28419 CLINICAL STAGE...........
28589 PATHOLOGIC STAGE.........
286NON CANCER-DIRECTED SURGERY
287CANCER-DIRECTED SURGERY
288HORMONE THERAPY
289 TABLE V - FIRST COURSE OF TREATMENT
290 51. DATE OF FIRST COURSE TREATMENT:
291 NON CANCER-DIRECTED SURGERY
292 52. DATE OF NON CANCER-DIRECTED
293 53. NON CANCER-DIRECTED SURGERY...:
294 CANCER-DIRECTED SURGERY
295 54. DATE (FIRST) OF CANCER-
296 DIRECTED SURGERY..............:
297 55. SURGICAL APPROACH.............:
298 56. SURGERY OF PRIMARY SITE.......:
299 57. SPECIMEN RADIOGRAPH...........: NA
300 57. SPECIMEN RADIOGRAPH...........: Unknown
301947 57. SPECIMEN RADIOGRAPH...........
302 58. SURGICAL MARGINS..............:
303#################### #################### ####################
304#################### #################### ####################
305#################### #################### ####################
306#################### #################### ####################
307#################### #################### ####################
Note: See TracBrowser for help on using the repository browser.